Iambic stock
Private-market facts for current and former Iambic employees researching their stock.
Overview
AI drug discovery company using deep learning models to predict protein-ligand interactions and accelerate small molecule drug development.
Iambic outlook
For employees evaluating Iambic equity, a 1x base multiple suggests the stock may be close to fairly valued at current prices. The upside scenario at 2x is relatively close to the base case, suggesting more predictable but narrower range of outcomes.
These estimates reflect modeled return scenarios, not guaranteed outcomes. Actual results depend on company performance, market conditions, share class, and timing.
Selling Iambic shares
Why shareholders consider selling
Shareholders in Iambic may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, Iambic does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.
Can you sell Iambic stock?
Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Healthcare & Biotech sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing Iambic shares would be outlined in the holder's equity agreement or the company's governing documents.
What affects the value of Iambic shares?
The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Healthcare & Biotech market conditions, and any recent private-market transaction activity. Data points such as the company's Series A round can help frame expectations, though they do not guarantee a transaction price.
What should holders check before selling
- The type of security held (common shares, preferred, options, RSUs)
- Whether the equity is fully vested and, for options, whether it has been exercised
- Any transfer restrictions, lock-up provisions, or company approval requirements
- Estimated net proceeds after applicable taxes and transaction fees
- Whether partial liquidity — selling a portion rather than the full position — may be a better fit
Tools for Iambic shareholders
Exploring equity in Iambic often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.
Latest funding round
Iambic most recently raised a Series A round . Total funding raised to date is approximately $60M.
Founders & company background
Iambic was founded in 2019 by Tom Miller and is headquartered in San Diego, CA.
Industry
Similar private companies
Latest Iambic news
Frequently asked questions
- Is Iambic still a private company?
- Yes, Iambic is currently a private company.
- What is Iambic's latest funding round?
- Iambic's most recent known round is Series A.
- What is Iambic's valuation?
- Iambic's valuation has not been publicly disclosed.
- Who are the investors in Iambic?
- Investor information is not currently available.
- Can I sell my Iambic stock?
- Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands Iambic stock can help you evaluate your options.
Related pages
Last verified: 2026-04-13 · Iambic data compiled from funding disclosures, corporate filings, and public records.
Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.